Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CONTACT<br />
Michael Altorfer, Ph.D.<br />
Head Corporate Development<br />
ADDRESS<br />
Hegenheimermattweg 125<br />
CH-4123 Allschwil<br />
Switzerland<br />
TELEPHONE<br />
+41 61 567 16 00<br />
FAX<br />
+41 61 567 16 01<br />
EMAIL<br />
info@polyphor.com<br />
michael.altorfer@polyphor.com<br />
YEAR FOUNDED<br />
1996<br />
Polyphor Ltd<br />
www.polyphor.com<br />
FINANCIAL SUMMARY<br />
Polyphor secured cash inflows through operational revenues and capital increases, each of which contributed<br />
roughly 50% to the total amount of close to 200 Mio. CHF.<br />
COMPANY PROFILE<br />
Corporate overview<br />
Polyphor is a Swiss research-driven pharmaceutical company developing innovative products with high<br />
therapeutic benefit to the patient and providing high quality support to its industry partners engaged in drug<br />
discovery.<br />
Polyphor has established two complementary innovative, proprietary technology platforms with the aim to<br />
discover and develop new medicines for unmet medical needs.<br />
Polyphor’s MacroFinder® and PEMfinder® platforms were specifically developed for discovering potent and<br />
selective modulators of Protein-Protein Interactions and other challenging targets.<br />
Products: Broadly diversified clinical and pre-clinical development portfolio<br />
• POL6326 (CXCR4 antagonist)<br />
• POL7080 (Pseudomonas-selective antibiotic, novel mode of action)<br />
• POL6014 (elastase inhibitor)<br />
• GPCR platform (e.g. CXCR7, CCR10)<br />
• Protease platform<br />
Platforms: Two proprietary technology platforms<br />
• PEMfinder®<br />
• MacroFinder®<br />
Partnering: R&D collaborations with Pharma partners<br />
• Boehringer Ingelheim<br />
• Novartis<br />
Clinical Development Pipeline:<br />
Polyphor’s competitive edge is based on its technology platforms which sustain a diversified portfolio of clinical<br />
candidates in various therapeutic areas.<br />
POL6326 (Phase II) – a CXCR4 antagonist that mobilizes stem cells from the bone marrow to the circulating<br />
blood. This effect can be exploited in several ways:<br />
• Stem cell transplantation (autologous and allogeneic).<br />
• Tissue repair.<br />
• Chemosensitization (CXCR4 antagonist to enhance impact of established anti-cancer therapies).<br />
POL7080 (Phase II ready) – highly potent Pseudomonas-selective antibiotic with novel mode of action.<br />
Successfully completed Phase I clinical trial. POL7080 has been shown to be highly efficacious against a broad<br />
panel of clinical isolates, including MDR Pseudomonas strains:<br />
• Phase II clinical trial planned to start in Q1, 2013.<br />
MANAGEMENT<br />
Jean-Pierre Obrecht Ph.D., Co-founder & CEO<br />
Daniel Obrecht Ph.D., Co-founder & CSO<br />
Christoph Rentsch, CFO<br />
Michael Altorfer Ph.D., Head Corporate Development<br />
Klaus Dembowsky M.D., Ph.D., Chief Medical Officer<br />
Marc Thommen Ph.D., Head Technology Platform<br />
Peter Zbinden Ph.D., Head Internal Services<br />
Helmut Kessmann Ph.D., Head Business Development<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS